Tas-102
Malignant Conjunctival Neoplasm
National Institutes of Health Clinical Center (CC)unclassifiedPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Malignant Conjunctival Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE National Institutes of Health Clinical Center (CC) | Phase 2 | CCC |
Cyclophosphamide National Institutes of Health Clinical Center (CC) | Phase 2 | CCC |
su011248 National Institutes of Health Clinical Center (CC) | Phase 2 | CCC |
cc-5013 National Institutes of Health Clinical Center (CC) | Phase 2 | CCC |
Tetanus Toxoid Helper Peptide Craig L Slingluff, Jr | Phase 1 | CC |
View all 9 →
Same molecule, other indications
Tas-102 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →